Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Sees Significant Decrease in Short Interest

Posted by Stephan Jacobs on Sep 29th, 2024

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG – Get Free Report) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 199,600 shares, a drop of 30.1% from the August 31st total of 285,500 shares. Currently, 3.8% of the company’s stock are sold short. Based on an average daily trading volume, of 202,100 shares, the short-interest ratio is presently 1.0 days.

Bullfrog AI Price Performance

Shares of NASDAQ:BFRG traded up $0.02 during midday trading on Friday, hitting $2.98. 120,441 shares of the company’s stock were exchanged, compared to its average volume of 983,709. Bullfrog AI has a 12 month low of $1.43 and a 12 month high of $8.35. The company has a market cap of $23.40 million, a PE ratio of -3.39 and a beta of -0.20. The stock has a 50 day moving average price of $2.63 and a 200-day moving average price of $2.73.

Bullfrog AI (NASDAQ:BFRG – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.20) earnings per share for the quarter.

Hedge Funds Weigh In On Bullfrog AI

Several institutional investors have recently bought and sold shares of BFRG. Fortem Financial Group LLC purchased a new position in shares of Bullfrog AI during the 1st quarter valued at $171,000. Renaissance Technologies LLC bought a new position in Bullfrog AI during the second quarter worth about $34,000. Finally, XTX Topco Ltd purchased a new position in shares of Bullfrog AI in the second quarter worth about $32,000. Hedge funds and other institutional investors own 0.96% of the company’s stock.

Bullfrog AI Company Profile

(Get Free Report)

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.